Polypeptide Treatment for Reversing Cataract Protein Aggregation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cataracts, the leading cause of blindness and severe visual impairment, are costly to treat surgically, and there is a need for effective, safe, and affordable alternatives.

Innovation Solution

Administering polypeptides with specific hydrophilic and hydrophobic segments capable of reversing phase separation to treat or prevent cataracts, using compositions that include polypeptides, polynucleotides, or vectors to target crystallin protein aggregates.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical treatment is used to treat cataracts, then treatment effectiveness is improved, but treatment cost increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment cost

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent replaces the mechanical surgical intervention (lens removal and replacement) with a biochemical treatment approach using polypeptides that target and dissolve crystallin protein aggregates. This substitution eliminates the need for invasive surgery while providing effective cataract treatment through molecular mechanisms.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent modifies the biochemical parameters of the lens proteins by introducing polypeptides that change the conformational state and solubility of crystallin proteins. This parameter change transforms the aggregated opaque proteins into soluble forms, reversing cataract opacity without surgical intervention.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If surgical treatment is used to treat cataracts, then treatment effectiveness is improved, but patient economic burden increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoideconomic burden

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent replaces expensive surgical procedures with affordable biochemical therapy. The polypeptide-based treatment eliminates the need for surgical facilities, anesthesia, and postoperative care, significantly reducing the economic burden on patients while maintaining treatment effectiveness.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent employs small, inexpensive polypeptide molecules (20-60 amino acid residues) that can be administered repeatedly at low cost. These small molecular agents replace expensive, invasive surgical procedures, providing an economically viable treatment option for patients.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Quantity of substance

If polypeptides are administered to treat cataracts, then treatment cost is reduced, but treatment mechanism complexity increases

Engineering Contradiction:

Improvetreatment costVSAvoidtreatment mechanism complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent segments the complex process of cataract treatment into a simple biochemical mechanism: polypeptides with specific hydrophilic and hydrophobic segments bind to crystallin protein aggregates, reversing phase separation and dissolving aggregates. This segmentation simplifies the treatment mechanism compared to complex surgical procedures.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent relies on fundamental biochemical parameter changes (hydrophilicity-hydrophobicity balance, amino acid sequence composition) to achieve treatment effects. These well-understood biochemical principles simplify the treatment mechanism while maintaining effectiveness, avoiding the complexity of surgical interventions.

Inventive Principle:

Principle #35Parameter changes

4Illumination intensity

If polypeptides are used to dissolve crystallin aggregates, then lens clarity is improved, but protein aggregation prevention becomes more difficult

Engineering Contradiction:

Improvelens clarityVSAvoidprotein aggregation prevention

Core Design Contradiction:

Illumination intensityVSEase of manufacture

Solution Approach 1:

The patent applies preliminary action by administering polypeptides that prevent crystallin protein aggregation in the first place. The polypeptides bind to exposed hydrophobic surfaces of crystallin proteins during early aggregation stages, preventing further aggregation and maintaining lens clarity before cataract development.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses polypeptides as intermediary agents that mediate between crystallin proteins and prevent their aggregation. These intermediary polypeptides bind to crystallin surfaces, sterically hindering protein-protein interactions and preventing aggregate formation, thereby maintaining lens transparency.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polypeptides effectively dissolve and prevent crystallin protein aggregates, potentially reversing phase separation and improving lens clarity, offering a non-surgical treatment option.

Implementation Method 1

the polypeptide is capable of reversing phase separation

Methodology Applied

Scientific EffectPhase separation: Phase Change

Data Source

PatentUS20250352611A1Methods for treating cataracts using polypeptides

Publication Date: 2025.11.20 RJK BIOPHARMA LTD

AI summary

Provided is a polypeptide capable of dissolving protein aggregates. Also provided is a method of treating a phase separation associated diseases, such as phase separation associated visual disorders (e.g., cataracts) using the polypeptide provided herein.